实验组的患者在化疗的基础上给予信迪利单抗治疗：静脉滴注信迪利单抗200

实验组的患者在化疗的基础上给予信迪利单抗治疗：静脉滴注信迪利单抗200mg、每3周1次【9】。观察指标分别于治疗前及治疗周期结束后，抽取晨起、空腹血清对比分析两组患者血清肿瘤标记物CYFRA211、CEA、CA125对比分析起变化情况以及两组患者T淋巴细胞亚群CD3+、CD4+、CD8+、CD4+/CD8+，对比分析两组患者变化水平；对比分析两组患者6个月时的临床疗效（近期疗效）。临床疗效判断方法【10】：完全缓解(CR)：病灶完全消失，肿瘤标志物检测结果恢复正常，且维持4周以上；部分缓解(PR)：病灶体积缩小30％以上，且维持4周以上；稳定(SD)：病灶体积缩小

0/5000

源语言: -

目标语言: -

结果 (英语) 1: [复制]

复制成功！

Patients in the experimental group were treated with Sintilizumab on the basis of chemotherapy: intravenous infusion of 200 mg Sintilizumab, once every 3 weeks [9]. Observation indicators were taken before treatment and after the end of the treatment cycle. The morning and fasting serum were taken to compare and analyze the changes in serum tumor markers CYFRA211, CEA, and CA125 of the two groups of patients, as well as the T lymphocyte subsets CD3+, CD4+, CD8+, CD4+/CD8+, comparative analysis of the changes in the two groups of patients; comparative analysis of the clinical efficacy (short-term efficacy) of the two groups at 6 months. Clinical efficacy judgment method [10]: Complete remission (CR): the lesion completely disappeared, and the tumor marker detection results returned to normal and maintained for more than 4 weeks; partial remission (PR): the lesion volume was reduced by more than 30% and maintained for more than 4 weeks ; Stable (SD): The size of the lesion is reduced

正在翻译中..

结果 (英语) 2:[复制]

复制成功！

实验组的患者在化疗的基础上给予信迪利单抗治疗：静脉滴注信迪利单抗200mg、每3周1次【9】。 观察指标 分别于治疗前及治疗周期结束后，抽取晨起、空腹血清对比分析两组患者血清肿瘤标记物CYFRA211、CEA、CA125对比分析起变化情况以及两组患者T淋巴细胞亚群CD3+、CD4+、CD8+、CD4+/CD8+，对比分析两组患者变化水平； 对比分析两组患者6个月时的临床疗效（近期疗效）。临床疗效判断方法【10】：完全缓解(CR)：病灶完全消失，肿瘤标志物检测结果恢复正常，且维持4周以上；部分缓解(PR)：病灶体积缩小30％以上，且维持4周以上；稳定(SD)：病灶体积缩小

正在翻译中..

结果 (英语) 3:[复制]

复制成功！

The patients in the experimental group were treated with sindilimab on the basis of chemotherapy: intravenous drip of sindilimab 200mg, once every 3 weeks [9]. Observation index Before treatment and after the treatment cycle, the serum tumor markers cyfra211, CEA and CA125 in the two groups were compared and analyzed, and the changes of T lymphocyte subsets CD3 +, CD4 +, CD8 +, CD4 + / CD8 + in the two groups were compared and analyzed; The clinical efficacy (short-term efficacy) of the two groups at 6 months was compared and analyzed. Methods of clinical efficacy judgment [10]: complete remission (CR): the lesion completely disappeared, and the tumor marker detection results returned to normal, and maintained for more than 4 weeks; partial response (PR): the lesion volume decreased by more than 30%, and maintained for more than 4 weeks; stable (SD): the lesion volume decreased

正在翻译中..

其它语言

本翻译工具支持: 世界语, 丹麦语, 乌克兰语, 乌兹别克语, 乌尔都语, 亚美尼亚语, 伊博语, 俄语, 保加利亚语, 信德语, 修纳语, 僧伽罗语, 克林贡语, 克罗地亚语, 冰岛语, 加利西亚语, 加泰罗尼亚语, 匈牙利语, 南非祖鲁语, 南非科萨语, 卡纳达语, 卢旺达语, 卢森堡语, 印地语, 印尼巽他语, 印尼爪哇语, 印尼语, 古吉拉特语, 吉尔吉斯语, 哈萨克语, 土库曼语, 土耳其语, 塔吉克语, 塞尔维亚语, 塞索托语, 夏威夷语, 奥利亚语, 威尔士语, 孟加拉语, 宿务语, 尼泊尔语, 巴斯克语, 布尔语(南非荷兰语), 希伯来语, 希腊语, 库尔德语, 弗里西语, 德语, 意大利语, 意第绪语, 拉丁语, 拉脱维亚语, 挪威语, 捷克语, 斯洛伐克语, 斯洛文尼亚语, 斯瓦希里语, 旁遮普语, 日语, 普什图语, 格鲁吉亚语, 毛利语, 法语, 波兰语, 波斯尼亚语, 波斯语, 泰卢固语, 泰米尔语, 泰语, 海地克里奥尔语, 爱尔兰语, 爱沙尼亚语, 瑞典语, 白俄罗斯语, 科西嘉语, 立陶宛语, 简体中文, 索马里语, 繁体中文, 约鲁巴语, 维吾尔语, 缅甸语, 罗马尼亚语, 老挝语, 自动识别, 芬兰语, 苏格兰盖尔语, 苗语, 英语, 荷兰语, 菲律宾语, 萨摩亚语, 葡萄牙语, 蒙古语, 西班牙语, 豪萨语, 越南语, 阿塞拜疆语, 阿姆哈拉语, 阿尔巴尼亚语, 阿拉伯语, 鞑靼语, 韩语, 马其顿语, 马尔加什语, 马拉地语, 马拉雅拉姆语, 马来语, 马耳他语, 高棉语, 齐切瓦语, 等语言的翻译.